DOCSLIB.ORG

Dictionary of Rheumatology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dictionary of Rheumatology Jozef Rovenský and Juraj Payer (eds.) Dictionary of Rheumatology With contributions by Roy B. Clague, Manfred Herold, Milan Bayer, Helena Tauchmannová, Miroslav Ferenčík, Zdenko Killinger SpringerWienNewYork Jozef Rovenský National Institute of Rheumatic Diseases, Piestany, Slovak Republic Juraj Payer 5th Department of Internal Medicine, Medical Faculty of Comenius University Faculty Hospital Bratislava-Ruzinov, Slovak Republic Roy B. Clague – Nobles Hospital, Isle of Man, UK Manfred Herold – Medical University of Innsbruck, Austria Milan Bayer – Faculty of Medicine in Hradec Kralove, Charles University Prague, Czech Republic Helena Tauchmannová – National Institute of Rheumatic Diseases, Piestany, Slovak Republic Miroslav Ferenčík – Institute of Neuroimmunology, Slovak Academy of Sciences and Institute of Immunology, Faculty of Medicine Comenius Universtiy, Bratislava, Slovak Republic Zdenko Killinger – 5th Department of Internal Medicine, Medical Faculty of Comenius University Faculty Hospital Bratislava-Ruzinov, Slovak Republic With financial support by Bundesministerium für Wissenschaft und Forschung in Wien, Austria. Sponsors, who thankfully granted the translation from Slovak into English: Eli Lilly Slovakia s.r.o., Bratislava; Servier Slovensko, spol. s.r.o., Bratislava; Novartis Slovakia s.r.o., Bratislava; Roche Slo- vensko, s.r.o., Bratislava; sanofi-aventis Pharma Slovakia, Bratislava. The printing was sponsored by: Teva Pharmaceutical, Bartislava, Slovakia; Novartis Slovakia s.r.o., Bratislava; Mayor of Piešťany, Slovakia. Parts of the book were translated from Rovenský et al. “Revmatologický výkladový slovník” GRADA Publishing, 2006 and Payer et al. “Lexikón osteoporózy” SAP, 2007. This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machines or similar means, and storage in data banks. Product Liability: The publisher can give no guarantee for all the information contained in this book. This does also refer to information about drug dosage and application thereof. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. This publication is compiled primarily from the publications Revmatologický výkladový slovník, Grada Publi- shing 2006 and Lexikón osteoporózy, Slovak Academic Press, 2007, together with latest findings. Project management, translation and compilation work: Language Sense Ltd. (John Boyd), Bratislava © 2009 Springer-Verlag/Wien Printed in Germany SpringerWienNewYork is a part of Springer Science + Business Media springer.at Typesetting: Composition & Design Services, Minsk 220027, Belarus Printing: Strauss GmbH, 69509 Mörlenbach, Germany Printed on acid-free and chlorine-free bleached paper SPIN: 11953708 Library of Congress Control Number: 2008940520 ISBN 978-3-211-68584-6 SpringerWienNewYork Preface This dictionary of rheumatology has tionary, we have taken into account the been prepared as a quick reference source fact that an integral part of prevention for the clinical, diagnostic and therapeu- and treatment of rheumatological dis- tic aspects of rheumatic disorders and eases includes rehabilitation. We there- related immunology. Rheumatology is a fore provided guidelines on how to pre- well-recognised specialty of medicine. vent the onset of functional damage and Recently, due to many factors (the envi- its progression towards increased dis- ronment, new viral diseases, genetics, ability. We believe this dictionary will increased life expectancy, improved di- serve not only rheumatologists, but also agnostic tests) an increase in the inci- the many related specialists, trainee doc- dence and prevalence of rheumatological tors, health professionals and nurses in- disorders has been witnessed. Rheuma- volved in the management of patients tology has close relationships with a num- with disorders of the human musculo- ber of medical specialties and health pro- skeletal system. fessionals, such as orthopaedic surgery, sports medicine, neurology, immunology, The early diagnosis and treatment of osteoporosis as well as clinical rheumatol- rheumatological disorders can help to ogy nurses, physiotherapists and occupa- improve their prognosis and we hope tional therapists, so we have endeavoured that this modest monograph will con- to collate some basic knowledge from tribute to a successful therapeutic man- these fields. When compiling this dic- agement. Jozef Rovenský On behalf of the collective authors A α1-antitrypsin A serum glycoprotein in- cellular processes that exert their action hibiting proteolytic enzymes, such as trypsin, mainly in blood coagulation, fibrinolysis and chymotrypsin and elastase. It also acts as an inflammation. α2M and protease complexes acute-phase protein. Its serum level rises in are proteolytically inactive and are eliminated inflammatory diseases. The coding gene is quickly (in minutes) from the circulation. Its located on the 14th chromosome, where it serum levels are increased especially in neph- can occur in form of 25 alleles. Some of them rotic syndrome, atopic dermatitis, diabetes code for physiological products (PiMM phe- mellitus and ataxia-telangiectasia. notype), while others are related to patho- logical states, e.g. PiZZ phenotype, which is Abatacept Abatacept (Orencia®) is an in- often associated with emphysema, cirrhosis, jectable, synthetic (man-made) soluble fusion and cholelithiasis, where its serum levels are protein that consists of the extracellular do- diminished (α1-antitrypsin deficiency). main of human cytotoxic T-lymphocyte-as- sociated antigen 4 (CTLA-4) linked to the α-fetoprotein An oncofetal antigen that modified Fc portion of human immunoglob- can be found in small concentrations in nor- ulin G1 (IgG1). Abatacept is produced by re- mal human serum. Its level is high in the fetal combinant DNA technology in a mammalian serum, where presumably thanks to its im- cell expression system. munosuppressive effect, it participates in Abatacept belongs to a new class of drugs neonatal immunological tolerance. The called costimulation modulators, shown to α-fetoprotein level is also increased in sera of inhibit T cell activation by binding to CD80 pregnant women when fetal development is and CD86, thereby blocking interaction with defective (central nervous system defects, im- CD28. Blockade of this interaction has been munodeficiency syndromes, gastrointestinal shown to inhibit the autoimmune T-Cell acti- or other abnormalities). An increased serum vation that has been implicated in the patho- level can be found in patients with certain genesis of rheumatoid arthritis Abatacept at- neoplastic disorders, especially hepatic can- taches to a protein on the surface of T-lym- cer and can be used as a marker of hepatocel- phocytes and blocks both the production of lular carcinoma. new T-lymphocytes and the production of the chemicals that destroy tissue and cause α1-microglobulin (α1M) A protein syn- the symptoms and signs of arthritis. Abata- thesised in the liver and present in blood, se- cept slows the damage to joints and cartilage rum and urine. Complexes of α1M with mo- and relieves the symptoms and signs of ar- nomeric immunoglobulin A (IgA) participate thritis. in renal IgA nephropathy where the serum Abatacept is indicated for reducing signs level of α2M is also usually increased. and symptoms, inducing major clinical re- sponse, slowing the progression of structural α2-macroglobulin (α2M) A serum glyco- damage, and improving physical function in protein working as inhibitor of a number of adult patients with moderately to severely ac- proteases including thrombin, plasmin, kal- tive rheumatoid arthritis who have had an in- likrein, trypsin, chymotrypsin, elastase, col- adequate response to one or more DMARDs, lagenase and cathepsin B and G. α2M is pro- such as methotrexate or TNF antagonists. duced mainly by macrophages and regulates Abatacept may be used as monotherapy or the proteolytic balance in a number of extra- concomitantly with DMARDs other than abduction 2 A TNF antagonists, but has not yet been ap- neus, separated from it by the Achilles bursa. proved by NICE. Tendonitis can be part of the clinical picture Approval of abatacept was supported by of spondyloarthritis, especially ankylosing five randomized, double-blind, placebo-con- spondylitis. It can remain thickened (by fi- trolled clinical trials. In all five studies, sub- brosis) after the inflammation has subsided jects received treatments with abatacept or and nodules may be palpable. placebo at weeks 0, 2, and 4, then every 4 weeks thereafter. Studies have found that Achillodynia Pain of the Achilles tendon, abatacept can reduce the signs and symptoms especially of its insertion, most frequently af- of rheumatoid arthritis. It can also reverse ter a trauma or sporting overload. some signs of joint damage. Abatacept/MTX slowed the progression of structural damage Achondroplasia and hypochondro- compared to placebo/MTX alone (Furst et al. plasia An autosomal dominant hereditary 2007). syndrome characterized by a small stature Abatacept is infused over 30 minutes. The with short extremities, in most cases
Load more

Recommended publications
  • Births, Marriages, and Deaths
    DEC. 31, 1955 MEDICAL NEWS MEDICALBRrsIJOURNAL. 1631 Lead Glazes.-For some years now the pottery industry British Journal of Ophthalmology.-The new issue (Vol. 19, has been forbidden to use any but leadless or "low- No. 12) is now available. The contents include: solubility" glazes, because of the risk of lead poisoning. EXPERIENCE IN CLINIcAL EXAMINATION OP CORNEAL SENsITiVrry. CORNEAL SENSITIVITY AND THE NASO-LACRIMAL REFLEX AFTER RETROBULBAR However, in some teaching establishments raw lead glazes or ANAES rHESIA. Jorn Boberg-Ans. glazes containing a high percentage of soluble lead are still UVEITIS. A CLINICAL AND STATISTICAL SURVEY. George Bennett. INVESTIGATION OF THE CARBONIC ANHYDRASE CONTENT OF THE CORNEA OF used. The Ministry of Education has now issued a memo- THE RABBIT. J. Gloster. randum to local education authorities and school governors HYALURONIDASE IN OCULAR TISSUES. I. SENSITIVE BIOLOGICAL ASSAY FOR SMALL CONCENTRATIONS OF HYALURONIDASE. CT. Mayer. (No. 517, dated November 9, 1955) with the object of INCLUSION BODIES IN TRACHOMA. A. J. Dark. restricting the use of raw lead glazes in such schools. The TETRACYCLINE IN TRACHOMA. L. P. Agarwal and S. R. K. Malik. APPL IANCES: SIMPLE PUPILLOMETER. A. Arnaud Reid. memorandum also includes a list of precautions to be ob- LARGE CONCAVE MIRROR FOR INDIRECT OPHTHALMOSCOPY. H. Neame. served when handling potentially dangerous glazes. Issued monthly; annual subscription £4 4s.; single copy Awards for Research on Ageing.-Candidates wishing to 8s. 6d.; obtainable from the Publishing Manager, B.M.A. House, enter for the 1955-6 Ciba Foundation Awards for research Tavistock Square, London, W.C.1.
    [Show full text]
  • Severe Septicaemia in a Patient with Polychondritis and Sweet's
    81 LETTERS Ann Rheum Dis: first published as 10.1136/ard.62.1.88 on 1 January 2003. Downloaded from Severe septicaemia in a patient with polychondritis and Sweet’s syndrome after initiation of treatment with infliximab F G Matzkies, B Manger, M Schmitt-Haendle, T Nagel, H-G Kraetsch, J R Kalden, H Schulze-Koops ............................................................................................................................. Ann Rheum Dis 2003;62:81–82 D Sweet first described an acute febrile neutrophilic dermatosis in 1964 characterised by acute onset, fever, Rleucocytosis, and erythematous plaques.1 Skin biopsy specimens show infiltrates consisting of mononuclear cells and neutrophils with leucocytoclasis, but without signs of vasculi- tis. Sweet’s syndrome is frequently associated with solid malig- nancies or haemoproliferative disorders, but associations with chronic autoimmune connective tissue disorders have also been reported.2 The aetiology of Sweet’s syndrome is unknown, but evidence suggests that an immunological reaction of unknown specificity is the underlying mechanism. CASE REPORT A 51 year old white man with relapsing polychondritis (first diagnosed in 1997) was admitted to our hospital in June 2001 with a five week history of general malaise, fever, recurrent arthritis, and complaints of morning stiffness. Besides Figure 1 autoimmune polychondritis, he had insulin dependent Manifestation of Sweet’s syndrome in a patient with relapsing polychondritis. diabetes mellitus that was diagnosed in 1989. On admission, he presented with multiple small to medium, sharply demarked, raised erythematous plaques on both fore- dose of glucocorticoids (80 mg) and a second application of http://ard.bmj.com/ arms and lower legs, multiple acne-like pustules on the face, infliximab (3 mg/kg body weight) were given.
    [Show full text]
  • Prescription Pattern of Primary Osteoarthritis in Tertiary Medical
    Published online: 2020-04-21 Running title: Primary Osteoarthritis Nitte University Journal of Health Science Original Article Prescription Pattern of Primary Osteoarthritis in Tertiary Medical Centre Sowmya Sham Kanneppady1, Sham Kishor Kanneppady2, Vijaya Raghavan3, Aung Myo Oo4, Ohn Mar Lwin5 1Senior Lecturer and Head, Department of Pharmacology, Faculty of Medicine, Lincoln University College, Selangor Darul Ehsan, Malaysia, 2Senior Lecturer, School of Dentistry, International Medical University, Kuala Lumpur, Malaysia, 3Head of the Department of Pharmacology, KVG Medical College and Hospital, Kurunjibag, Sullia, Karnataka, India. 4Assistant Professor, Department of Biochemistry, Faculty of Medicine, Lincoln University College, Selangor Darul Ehsan, Malaysia, 5Post graduate student, Department of Physiology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia. *Corresponding Author : Sowmya Sham Kanneppady, Senior Lecturer and Head,Department of Pharmacology, Faculty of Medicine, Lincoln University College, No. 2, Jalan Stadium, SS 7/15, Kelana Jaya, 47301, Petaling Jaya, Selangor Darul Ehsan, Malaysia. E-mail : [email protected]. Received : 12.10.2017 Abstract Review Completed : 05.12.2017 Objectives: Osteoarthritis (OA) is one of the commonest joint/musculoskeletal disorders, Accepted : 06.12.2017 affecting the middle aged and elderly, although younger people may be affected as a result of injury or overuse. The study aimed to analyze the data, evaluate the prescription pattern and Keywords: Osteoarthritis, anti- rationality of the use of drugs in the treatment of primary OA with due emphasis on the inflammatory agents, prevalence available treatment regimens. Materials and methods: Medical case records of patients suffering from primary OA attending Access this article online the department of Orthopedics of a tertiary medical centre were the source of data.
    [Show full text]
  • Acute < 6 Weeks Subacute ~ 6 Weeks Chronic >
    Pain Articular Non-articular Localized Generalized . Regional Pain Disorders . Myalgias without Weakness Soft Tissue Rheumatism (ex., fibromyalgia, polymyalgia (ex., soft tissue rheumatism rheumatica) tendonitis, tenosynovitis, bursitis, fasciitis) . Myalgia with Weakness (ex., Inflammatory muscle disease) Clinical Features of Arthritis Monoarthritis Oligoarthritis Polyarthritis (one joint) (two to five joints) (> five joints) Acute < 6 weeks Subacute ~ 6 weeks Chronic > 6 weeks Inflammatory Noninflammatory Differential Diagnosis of Arthritis Differential Diagnosis of Arthritis Acute Monarthritis Acute Polyarthritis Inflammatory Inflammatory . Infection . Viral - gonococcal (GC) - hepatitis - nonGC - parvovirus . Crystal deposition - HIV - gout . Rheumatic fever - calcium . GC - pyrophosphate dihydrate (CPPD) . CTD (connective tissue diseases) - hydroxylapatite (HA) - RA . Spondyloarthropathies - systemic lupus erythematosus (SLE) - reactive . Sarcoidosis - psoriatic . - inflammatory bowel disease (IBD) Spondyloarthropathies - reactive - Reiters . - psoriatic Early RA - IBD - Reiters Non-inflammatory . Subacute bacterial endocarditis (SBE) . Trauma . Hemophilia Non-inflammatory . Avascular Necrosis . Hypertrophic osteoarthropathy . Internal derangement Chronic Monarthritis Chronic Polyarthritis Inflammatory Inflammatory . Chronic Infection . Bony erosions - fungal, - RA/Juvenile rheumatoid arthritis (JRA ) - tuberculosis (TB) - Crystal deposition . Rheumatoid arthritis (RA) - Infection (15%) - Erosive OA (rare) Non-inflammatory - Spondyloarthropathies
    [Show full text]
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • Axial Spondyloarthritis
    Central JSM Arthritis Review Article *Corresponding author Mali Jurkowski, Department of Internal Medicine, Temple University Hospital, 3401 North Broad Street, Axial Spondyloarthritis: Clinical Philadelphia, PA 19140, USA Submitted: 07 December 2020 Features, Classification, and Accepted: 31 January 2021 Published: 03 February 2021 ISSN: 2475-9155 Treatment Copyright Mali Jurkowski1*, Stephanie Jeong1 and Lawrence H Brent2 © 2021 Jurkowski M, et al. 1Department of Internal Medicine, Temple University Hospital, USA OPEN ACCESS 2Section of Rheumatology, Department of Medicine, Lewis Katz School of Medicine at Temple University, USA Keywords ABBREVIATIONS • Spondyloarthritis • Ankylosing spondylitis HLA-B27: human leukocyte antigen-B27; SpA: • HLA-B27 spondyloarthritis; AS: ankylosing spondylitis; nr-axSpA: non- • Classification criteria radiographic axial spondyloarthritis; ReA: reactive arthritis; PsA: psoriatic arthritis; IBD-SpA: disease associated spondyloarthritis; ASAS: Assessment of of rheumatoid arthritis [6]. AS affects men more than women SpondyloArthritis international Society; NSAIDs:inflammatory nonsteroidal bowel 79.6%, whereas nr-axSpA affects men and women equally 72.4% CASPAR: [7], independent of HLA-B27. This article will discuss the clinical for Psoriatic Arthritis; DMARDs: disease modifying anti- and diagnostic features of SpA, compare the classification criteria, rheumaticanti-inflammatory drugs; CD:drugs; Crohn’s disease; ClassificationUC: ulcerative Criteriacolitis; and provide updates regarding treatment options, including the ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; developmentCLINICAL FEATURESof biologics and targeted synthetic agents. TNFi: X-ray: plain radiography; MRI: magnetic resonance imaging; CT: computed Inflammatory back pain tomography;tumor US: necrosis ultrasonography; factor-α wb-MRI:inhibitors; ESSG: European Spondyloarthropathy Study Group; IL-17i: whole-body MRI; JAKi: PDE4i: Inflammatory back pain is the hallmark of SpA, present in 70- 80% of patients [8].
    [Show full text]
  • Marble Bone Disease: a Rare Bone Disorder
    Open Access Case Report DOI: 10.7759/cureus.339 Marble Bone Disease: A Rare Bone Disorder Eswaran Arumugam 1 , Maheswari Harinathbabu 2 , Ranjani Thillaigovindan 1 , Geetha Prabhu 1 1. Prosthodontics, Thai Moogambigai Dental College and Hospital 2. Oral Medicine and Radiology, Siva Multi Speciality Dental Clinic Corresponding author: Eswaran Arumugam, [email protected] Abstract Osteopetrosis, or marble bone disease, is a rare skeletal disorder due to a defective function of the osteoclasts. This defect renders bones more susceptible to osteomyelitis due to decreased vascularity. This disorder is inherited as autosomal dominant and autosomal recessive. Healthcare professionals should urge these patients to maintain their oral health as well as general health, as this condition makes these patients more susceptible to frequent infections and fractures. This case report emphasizes the signs and symptoms of marble bone disease and presents clinical and radiographic findings. Categories: Physical Medicine & Rehabilitation, Miscellaneous Keywords: osteopetrosis, marble bone disease, autosomal recessive, dense sclerotic bone Introduction Osteopetrosis (literally "stone bone," also known as marble bone disease or Albers-Schonberg disease) is an extremely rare inherited disorder where the bones harden and become denser. The disorder can cause osteosclerosis. The estimated prevalence of osteopetrosis is 1 in 100,000 to 500,000. It presents in two major clinical forms-a benign autosomal dominant form and a malignant autosomal recessive form. The autosomal dominant adult (benign) form is associated with few, if any, symptoms, and the autosomal recessive infantile (malignant) form is typically fatal during infancy or early childhood if untreated [1]. A rarer autosomal recessive (intermediate) form presents during childhood with some signs and symptoms of malignant osteopetrosis.
    [Show full text]
  • Experiences of Rare Diseases: an Insight from Patients and Families
    Experiences of Rare Diseases: An Insight from Patients and Families Unit 4D, Leroy House 436 Essex Road London N1 3QP tel: 02077043141 fax: 02073591447 [email protected] www.raredisease.org.uk By Lauren Limb, Stephen Nutt and Alev Sen - December 2010 Web and press design www.raredisease.org.uk WordsAndPeople.com About Rare Disease UK Rare Disease UK (RDUK) is the national alliance for people with rare diseases and all who support them. Our membership is open to all and includes patient organisations, clinicians, researchers, academics, industry and individuals with an interest in rare diseases. RDUK was established by Genetic RDUK is campaigning for a Alliance UK, the national charity strategy for integrated service of over 130 patient organisations delivery for rare diseases. This supporting all those affected by would coordinate: genetic conditions, in conjunction with other key stakeholders | Research in November 2008 following the European Commission’s | Prevention and diagnosis Communication on Rare Diseases: | Treatment and care Europe’s Challenges. | Information Subsequently RDUK successfully | Commissioning and planning campaigned for the adoption of the Council of the European into one cohesive strategy for all Union’s Recommendation on patients affected by rare disease in an action in the field of rare the UK. As well as securing better diseases. The Recommendation outcomes for patients, a strategy was adopted unanimously by each would enable the most effective Member State of the EU (including use of NHS resources. the
    [Show full text]
  • Hypophosphatasia: Current Literature for Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment
    Open Access Review Article DOI: 10.7759/cureus.8594 Hypophosphatasia: Current Literature for Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment Abdulai Bangura 1 , Lisa Wright 2 , Thomas Shuler 2 1. Department of Research, Trinity School of Medicine, Ratho Mill, VCT 2. Department of Orthopaedics, Carilion Clinic, Roanoke, USA Corresponding author: Abdulai Bangura, [email protected] Abstract Hypophosphatasia (HPP) is a rare inherited bone disorder identified by impaired bone mineralization. There are seven subtypes of HPP mainly characterized by their age of onset. These subtypes consist of perinatal (prenatal) benign, perinatal lethal, infantile, childhood, adult, odontohypophosphatasia, and pseudohypophosphatasia. Due to limited awareness of the condition, either misdiagnosis or delayed diagnosis is common. Furthermore, the condition is frequently treated with contraindicated drugs. This literature illustrates the most recent findings on the etiology, pathophysiology, clinical manifestations, diagnosing, and treatment for HPP and its subtypes. The etiology of the disease consists of loss-of-function mutations of the ALPL gene on chromosome one, which encodes for tissue nonspecific isoenzyme of alkaline phosphatase (TNAP). A decrease of TNAP reduces inorganic phosphate (Pi) for bone mineralization and allows for an increase in inorganic pyrophosphate (PPi) and phosphorylated osteopontin (p-OPN), which further reduces bone mineralization. The combination of these processes softens bone and mediates a clinical presentation similar to rickets/osteomalacia. HPP has an additional wide range of clinical features depending on its subtype. Although a concrete diagnostic guideline has not yet been established, many studies have supported a similar method of identifying HPP. Clinical features, radiological findings, and/or biomarker levels of the disorder should raise suspicion and encourage the inclusion of HPP as a differential diagnosis.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Osteomalacia and Osteoporosis D
    Postgrad. med.J. (August 1968) 44, 621-625. Postgrad Med J: first published as 10.1136/pgmj.44.514.621 on 1 August 1968. Downloaded from Osteomalacia and osteoporosis D. B. MORGAN Department of Clinical Investigation, University ofLeeds OSTEOMALACIA and osteoporosis are still some- in osteomalacia is an increase in the alkaline times confused because both diseases lead to a phosphatase activity in the blood (SAP); there deficiency of calcium which can be detected on may also be a low serum phosphorus or a low radiographs of the skeleton. serum calcium. This lack of calcium is the only feature Our experience with the biopsy of bone is that common to the two diseases which are in all a large excess of uncalcified bone tissue (osteoid), other ways easily distinguishable. which is the classic histological feature of osteo- malacia, is only found in patients with the other Osteomalacia typical features of the disease, in particular the Osteomalacia will be discussed first, because it clinical ones (Morgan et al., 1967a). Whether or is a clearly defined disease which can be cured. not more subtle histological techniques will detect Osteomalacia is the result of an imbalance be- earlier stages of the disease remains to be seen. tween the supply of and the demand for vitamin Bone pains, muscle weakness, Looser's zones, D. The the following description of disease is raised SAP and low serum phosphate are the Protected by copyright. based on our experience of twenty-two patients most reliable aids to the diagnosis of osteomalacia, with osteomalacia after gastrectomy; there is no and approximately in that order.
    [Show full text]
  • A Resident's Guide to Pediatric Rheumatology
    A RESIDENT’S GUIDE TO PEDIATRIC RHEUMATOLOGY 4th Revised Edition - 2019 A RESIDENT’S GUIDE TO PEDIATRIC RHEUMATOLOGY This guide is intended to provide a brief introduction to basic topics in pediatric rheumatology. Each topic is accompanied by at least one up-to-date reference that will allow you to explore the topic in greater depth. In addition, a list of several excellent textbooks and other resources for you to use to expand your knowledge is found in the Appendix. We are interested in your feedback on the guide! If you have comments or questions, please feel free to contact us via email at [email protected]. Supervising Editors: Dr. Ronald M. Laxer, SickKids Hospital, University of Toronto Dr. Tania Cellucci, McMaster Children’s Hospital, McMaster University Dr. Evelyn Rozenblyum, St. Michael’s Hospital, University of Toronto Section Editors: Dr. Michelle Batthish, McMaster Children’s Hospital, McMaster University Dr. Roberta Berard, Children’s Hospital – London Health Sciences Centre, Western University Dr. Liane Heale, McMaster Children’s Hospital, McMaster University Dr. Clare Hutchinson, North York General Hospital, University of Toronto Dr. Mehul Jariwala, Royal University Hospital, University of Saskatchewan Dr. Lillian Lim, Stollery Children’s Hospital, University of Alberta Dr. Nadia Luca, Alberta Children’s Hospital, University of Calgary Dr. Dax Rumsey, Stollery Children’s Hospital, University of Alberta Dr. Gordon Soon, North York General Hospital and SickKids Hospital Northern Clinic in Sudbury, University
    [Show full text]